News

Solomon L Moshe, MD, and Elissa Yozawitz, MD, from Montefiore Medical Center, discussed ways of reducing misdiagnosis of neonatal seizures and the future work needed to be done in this space.

A recent publication describes the findings of two initiatives to evaluate and raise awareness about the impact that SMA has on adolescents and young adults.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed whether lenalidomide, a repurposed cancer drug, has promise as an Alzheimer disease DMT.

Just over half (53%) of patients treated with the amantadine extended-release agent had greater than 50% reduction in time spent ON with dyskinesia and just over a quarter (27%) of patients had greater than 75% reduction.

The duo from the National Institutes of Health discussed the advantages of the ultra-high resolution imaging technology in research.

Preliminary results from the IGNITE-DMD trial also showed a decreased in creatine kinase levels and improvements on NSAA and PODCI.

Progressive forms of multiple sclerosis present a number of challenges for MS specialists, the biggest of which being whether or not disease-modifying therapy is required.

The postdoctoral researcher at Columbia University discussed the long-term plans to gain a better understanding of MS diagnosis disclosure and how it can impact other qualities of life.

Researchers studied associations between obstructive sleep apnea and varied markers of adiposity.

Dosing will be paused in the open-label extension study (GEN-EXTEND) of tominersen while data are carefully analyzed to inform next steps on this study.

Researchers at NYU Grossman School of Medicine clarified the role of GNB1, which may be a strong target for epilepsy therapies.

The fellow of autoimmune neurology at Massachusetts General Hospital also discussed concerns of associations between multiple sclerosis and COVID-19.

If approved, daridorexant would become the first sleep medication to demonstrate an improvement in sleep and daytime functioning, while keeping a favorable safety profile in adult and elderly patients.

A recent study investigated the natural history of Dravet Syndrome in adults.

In the phase 3 ADVANCE trial, all active treatment arms of atogepant met their primary end point, and the 30-mg and 60-mg doses met all 6 secondary end points with statistical significance.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed the reasons behind the lack of real-world dementia studies.

Researchers found that taking into account PWA increased total arousal index more than 3-fold.

The SNP-targeting agents showed no evidence of dose response in PRECISION-HD2 and similar results in PRECISION-HD1, though development of SNP3-targeted agent WVE-003 in HD will continue.

Researchers conducted a systematic review of studies reporting on patients with both COVID-19 and stroke and found worse outcomes compared to patients with stroke alone.

Patients treated with NurOwn showed a mean improvement from baseline of 10% in timed 25-foot walk and a 4.9% improvement from baseline on the 9-hole peg test dominant hand.

The PhD candidate at the Barts MS Center in London discussed her study presented at ACTRIMS Forum 2021 that evaluated CPD in patients with relapsing MS.

The PoNS device becomes the first and only medical device cleared in the US for short-term treatment of gait in patients with multiple sclerosis.

The duo from Montefiore Medical Center detailed the reasons why EEGs must remain an interictal part in improving rates of misdiagnosing neonatal seizures.

Here's what is coming soon to NeurologyLive.

Howard Fillit, MD, the founding executive director and chief science officer, Alzheimer's Drug Discovery Foundation, shared his thoughts on the recently published data.

The Adults with SMA Virtual Therapy Program is sponsored by Genentech and the Dhont Family Foundation.

Researchers analyzed levels of sGFAP in participants from the N-MOmentum study that assessed inebilizumab (Uplizna; Viela Bio) in relapsing-remitting MS.

Researchers observed improvements in motor and respiratory function and biomarkers in the investigational treatment group.